MDT

82.84

-0.02%↓

VEEV

211.75

-0.9%↓

A

103.17

+2.65%↑

HQY

79.53

+3.96%↑

PDCO

30.84

-0.32%↓

MDT

82.84

-0.02%↓

VEEV

211.75

-0.9%↓

A

103.17

+2.65%↑

HQY

79.53

+3.96%↑

PDCO

30.84

-0.32%↓

MDT

82.84

-0.02%↓

VEEV

211.75

-0.9%↓

A

103.17

+2.65%↑

HQY

79.53

+3.96%↑

PDCO

30.84

-0.32%↓

MDT

82.84

-0.02%↓

VEEV

211.75

-0.9%↓

A

103.17

+2.65%↑

HQY

79.53

+3.96%↑

PDCO

30.84

-0.32%↓

MDT

82.84

-0.02%↓

VEEV

211.75

-0.9%↓

A

103.17

+2.65%↑

HQY

79.53

+3.96%↑

PDCO

30.84

-0.32%↓

Search

Emergent BioSolutions Inc

Closed

SectorHealthcare

4.49 -7.04

Overview

Share price change

24h

Current

Min

4.41

Max

4.53

Key metrics

By Trading Economics

Income

-146M

-31M

Sales

-105M

189M

EPS

-0.578

Profit margin

-16.535

Employees

900

EBITDA

-164M

13M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+231.86% upside

Dividends

By Dow Jones

Next Earnings

30 kwi 2025

Market Stats

By TradingEconomics

Market Cap

420M

540M

Previous open

11.53

Previous close

4.49

News Sentiment

By Acuity

50%

50%

133 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Emergent BioSolutions Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 kwi 2025, 22:38 UTC

Hot Stocks

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

7 kwi 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy: Stonepeak's Total Contribution Lower Than Nominal Equity Interest Give Accelerated Spend

6 kwi 2025, 23:58 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy: Deal 'a Material Step' Toward Readiness for Final Investment Decision

6 kwi 2025, 23:58 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy: Deal 'Significantly Reduces' Company's Capex Profile

6 kwi 2025, 23:57 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy: Stonepeak to Contribute 75% of Project Capex in Both 2025, 2026

6 kwi 2025, 23:57 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy: Stonepeak to Provide $5.7 Billion Towards Expected Project Capex

6 kwi 2025, 23:57 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 kwi 2025, 23:57 UTC

Market Talk

Nervous Start For AUD/USD; Watch on CNY Fix -- Market Talk

6 kwi 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy: Signs Deal With Stonepeak for Sale of 40% Interest in Louisiana LNG Infrastructure

6 kwi 2025, 23:52 UTC

Market Talk

Gold Slips; Likely Unwinding of Long Positions to Raise Cash -- Market Talk

6 kwi 2025, 23:39 UTC

Market Talk

Oil Futures Slide on Fears of Weakening Global Demand -- Market Talk

6 kwi 2025, 23:39 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Weigh on Global Econ Outlook -- Market Talk

6 kwi 2025, 23:39 UTC

Market Talk

Global Equities Roundup: Market Talk

6 kwi 2025, 23:38 UTC

Acquisitions, Mergers, Takeovers

Challenger: Reinsurance Relationship With MS Primary Will Continue

6 kwi 2025, 23:38 UTC

Acquisitions, Mergers, Takeovers

Challenger: Acquisition at 53% Premium to Most Recent Share Price

6 kwi 2025, 23:37 UTC

Acquisitions, Mergers, Takeovers

Challenger: Acquisition Subject to Regulatory Approvals

6 kwi 2025, 23:36 UTC

Acquisitions, Mergers, Takeovers

Challenger: Dai-ichi Life Acquiring Stake From MS&AD Insurance

6 kwi 2025, 23:36 UTC

Acquisitions, Mergers, Takeovers

Challenger: Dai-ichi Life Paying About A$8.46/Share

6 kwi 2025, 23:35 UTC

Acquisitions, Mergers, Takeovers

Challenger: Dai-ichi Life Agrees to Acquire 15.1% Interest

6 kwi 2025, 21:58 UTC

Top News

Bitcoin Is Falling Amid Global Market Swoon -- Barrons.com

6 kwi 2025, 13:00 UTC

Top News

Trump Promised to Lower Energy Prices -- But It Wasn't Supposed to Be Like This -- WSJ

5 kwi 2025, 15:45 UTC

Top News

Republicans Advance Trump's Tax Cuts After Late-Night Session -- Update

5 kwi 2025, 15:00 UTC

Top News

U.S.-Stock Funds Have a Quarter to Forget -- Journal Report

5 kwi 2025, 15:00 UTC

Top News

The Complicated Relationship Between Consumer Sentiment and Stocks -- Journal Report

5 kwi 2025, 14:38 UTC

Top News

Trump's Trade Broadside Puts Chinese Economy Under Heavy Pressure -- WSJ

5 kwi 2025, 06:44 UTC

Top News

Republicans Advance Trump's Tax Cuts After Late-Night Session -- WSJ

5 kwi 2025, 01:00 UTC

Acquisitions, Mergers, Takeovers

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ

5 kwi 2025, 01:00 UTC

Acquisitions, Mergers, Takeovers

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ -2-

4 kwi 2025, 21:53 UTC

Market Talk

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 kwi 2025, 21:44 UTC

Top News
Acquisitions, Mergers, Takeovers

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

Peer Comparison

Price change

Emergent BioSolutions Inc Forecast

Price Target

By TipRanks

231.86% upside

12 Months Forecast

Average 15 USD  231.86%

High 15 USD

Low 15 USD

Based on 1 Wall Street analysts offering 12 month price targets forEmergent BioSolutions Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

N/A / 5.1664Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

133 / 386 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.